How have CYDY shares performed in 2024?

CytoDyn's stock was trading at $0.1950 on January 1st, 2024. Since then, CYDY shares have decreased by 22.6% and is now trading at $0.1509. View the best growth stocks for 2024 here .

Are investors shorting CytoDyn?

CytoDyn saw a drop in short interest in March. As of March 31st, there was short interest totaling 4,680,600 shares, a drop of 8.4% from the March 15th total of 5,107,100 shares. Based on an average daily trading volume, of 2,871,500 shares, the days-to-cover ratio is currently 1.6 days. View CytoDyn's Short Interest .

How were CytoDyn's earnings last quarter?

CytoDyn Inc. (OTCMKTS:CYDY) issued its quarterly earnings data on Monday, April, 15th. The biotechnology company reported ($0.01) earnings per share for the quarter.

What other stocks do shareholders of CytoDyn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO) , Novavax (NVAX) , NVIDIA (NVDA) , Johnson & Johnson (JNJ) , Gilead Sciences (GILD) , Vaxart (VXRT) , Nokia Oyj (NOK) , Pfizer (PFE) , Sorrento Therapeutics (SRNE) and Moderna (MRNA) .

How do I buy shares of CytoDyn?

Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:CYDY

CytoDyn (CYDY) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free CYDY Stock Alerts

$0.15

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.14
▼
$0.16
50-Day Range: $0.15
▼
$0.26
52-Week Range: $0.13
▼
$0.42

Volume: 806,934 shs
Average Volume: 1.46 million shs
Market Capitalization: $149.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

Get CytoDyn alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About CytoDyn Stock (OTCMKTS:CYDY)

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

CYDY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYDY Stock News Headlines

April 15, 2024 | americanbankingnews.com

Financial Contrast: Societal CDMO (NASDAQ:SCTL) & CytoDyn (OTCMKTS:CYDY)

February 29, 2024 | markets.businessinsider.com

CytoDyn Says FDA Lifts Hold On Leronlimab

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 29, 2024 | msn.com

FDA lifts clinical hold on CytoDyn drug, stock rallies 22%

February 29, 2024 | globenewswire.com

CytoDyn Announces FDA Has Lifted Clinical Hold

February 10, 2024 | morningstar.com

CytoDyn Inc CYDY

February 1, 2024 | markets.businessinsider.com

CytoDyn Submits Revised HIV Clinical Trial Protocol To FDA, Starts Glioblastoma Pre-Clinical Study

February 1, 2024 | finance.yahoo.com

CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 1, 2024 | tmcnet.com

CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

January 31, 2024 | bizjournals.com

Investors file another lawsuit against CytoDyn

January 30, 2024 | msn.com

CytoDyn Releases Regulatory FD Disclosure Information

January 30, 2024 | msn.com

CytoDyn Announces Executive Leadership Changes and Appointments

January 29, 2024 | bizjournals.com

Vancouver biotech appoints new CEO, as former top executive awaits fraud trial

January 29, 2024 | finanznachrichten.de

CytoDyn Inc.: CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO

January 29, 2024 | msn.com

CytoDyn appoints Jacob Lalezari as CEO, Mitchell Cohen as interim CFO

January 29, 2024 | finance.yahoo.com

CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO

December 7, 2023 | finance.yahoo.com

CytoDyn Announces Webcast to Provide Company Update

November 22, 2023 | msn.com

CytoDyn appoints Lalezari as its interim CEO

November 21, 2023 | finanznachrichten.de

CytoDyn Inc.: CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO

November 21, 2023 | finance.yahoo.com

CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO

September 21, 2023 | bizjournals.com

Former biotech execs in 'brazen fraud' case want indictments dismissed

August 2, 2023 | fool.com

CytoDyn (OTC: CYDY)

July 24, 2023 | bizjournals.com

CytoDyn leader on taking HIV treatment back to FDA, is upbeat about Amarex litigation

July 13, 2023 | benzinga.com

Developments in OTC Stocks Under a Quarter (CSTF, CYDY, IMHC, BRLL)

July 12, 2023 | bizjournals.com

CytoDyn hits up former business partner for $100M in damages

July 11, 2023 | finance.yahoo.com

CytoDyn Announces Company Updates and Investment Community Update Webcast

See More Headlines

Receive CYDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytoDyn and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/15/2024
Today: 4/18/2024
Fiscal Year End: 5/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:CYDY
Previous Symbol: NASDAQ:CYDY
CUSIP: 23283M101
CIK: 1175680
Web: www.cytodyn.com
Phone: (360) 980-8524
Fax: N/A
Employees: 12
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-79,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -478.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.08
Quick Ratio: 0.07

Sales & Book Value

Annual Sales: $270,000.00
Price / Sales: 554.72
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.12) per share
Price / Book: -1.26

Miscellaneous

Outstanding Shares: 992,870,000
Free Float: 985,823,000
Market Cap: $149.77 million
Optionable: Not Optionable
Beta: 0.16

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Cyrus Arman M.B.A. (Age 42)
Ph.D., Senior Vice President of Business Operations
Comp: $451.17k
Dr. Jacob P. Lalezari M.D. (Age 64)
CEO & Member of Scientific Advisory Board
Mr. Mitchell Cohen (Age 67)
Interim Chief Financial Officer
Mr. Tyler Blok (Age 36)
Executive Vice President of Legal Affairs & Secretary
Dr. Scott Hansen Ph.D.
Head of Research & Basic Science
Mr. Joseph Meidling
Executive Director of Clinical Operations
Ms. Cristina De Leon
Investors

Key Competitors

View All Competitors

CYDY Stock Analysis - Frequently Asked Questions

How have CYDY shares performed in 2024?: CytoDyn's stock was trading at $0.1950 on January 1st, 2024. Since then, CYDY shares have decreased by 22.6% and is now trading at $0.1509.
View the best growth stocks for 2024 here.
Are investors shorting CytoDyn?: CytoDyn saw a drop in short interest in March. As of March 31st, there was short interest totaling 4,680,600 shares, a drop of 8.4% from the March 15th total of 5,107,100 shares. Based on an average daily trading volume, of 2,871,500 shares, the days-to-cover ratio is currently 1.6 days.
View CytoDyn's Short Interest.
How were CytoDyn's earnings last quarter?: CytoDyn Inc. (OTCMKTS:CYDY) issued its quarterly earnings data on Monday, April, 15th. The biotechnology company reported ($0.01) earnings per share for the quarter.

What other stocks do shareholders of CytoDyn own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CytoDyn investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), NVIDIA (NVDA), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Vaxart (VXRT), Nokia Oyj (NOK), Pfizer (PFE), Sorrento Therapeutics (SRNE) and Moderna (MRNA).
How do I buy shares of CytoDyn?: Shares of CYDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CYDY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CytoDyn (CYDY) Stock Price, News & Analysis

About CytoDyn Stock (OTCMKTS:CYDY)

CYDY Stock Price History

CYDY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CYDY Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info